Health Technology Assessment in Portugal: health policies, methodologies and emerging challenges
DOI:
https://doi.org/10.30968/rbfhss.2022.133.0861Abstract
Portugal is a European country with a high Human Development Index (HDI) and extensive health system coverage. In line with the recommendations of the World Health Organization, Portugal regulates drug prices to ensure better access with financial sustainability. To this aim, health technology assessment is recognized as an essential tool for making informed financing decisions. In consonance with the challenges faced by other countries in this domain in the last few years, the methodologies and criteria used in the evaluation of different health technologies have been put to the test. This article presents an overview of the Portuguese health system and the technology assessment system regarding the latest main implemented policies also on the price regulation system, including the most recent challenges faced in this field.
Downloads
References
UNDP. Report of Human Development. 2020 Available in: https://hdr.undp.org/sites/default/files/hdr_2020_overview_portuguese.pdf. Accessed on: 12 Apr 2022.
National Institute of Statistics (INE). Population residing in Portugal by place of residence. Available in: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_indicadores&contecto=pi&indOcorrCod=0011166&selTab=tab0. Accessed on: 26 Apr 2022.
National Institute of Statistics (INE). Territory and population density in Portugal. Available in: https://www.ine.pt/xportal/xmain?xpgid=ine_tema&xpid=INE&tema_cod=1211. Accessed on: 26 Apr 2022.
The World Bank. CountryProfile | World Development Indicators. 2020. Available in: https://databank.worldbank.org/views/reports/reportwidget.aspx?Report_Name=CountryProfile&Id=b450fd57&tbar=y&dd=y&inf=n&zm=n&country=PRT. Accessed on: 12 Apr 2022.
UNDP. Report of Human Development. 2020.
World Bank. Gini index (World Bank estimate) - United | Date. 2019. Available in: https://data.worldbank.org/indicator/SI.POV.GINI?locations=PT&view=chart. Accessed on: 2 Apr 2022.
Organization for Economic Cooperation and Development (OECD). Portugal: Country Health Profile 2021. Country Health Profile 2021. OECD; 2021; DOI: 10.1787/766C3111-EN.
OECD. Purchasing Power Parities (PPP). OECD; 2022 Available in: https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm#indicator-chart.DOI: 10.1787/9789264189232-EN. Accessed on: 13 Apr 2022.
Kulesher RR, Elizabeth Forrestal E. International models of health systems financing. Journal of Hospital Administration. 2014;3(4):127–139. DOI: 10.5430/jha.v3n4p127.
Cantante AP da SR, Fernandes HIVM, Teixeira MJ, et al. Health Systems and Nursing Skills in Portugal. Science & Public Health. ABRASCO - Brazilian Association of Public Health; 2019;25(1):261–272. DOI: 10.1590/1413-81232020251.27682019.
Pricing P, Information R. PPRI Pharma Profile Portugal. 2008;(October).
Vogler S, Leopold C. Access to Essential Medicines in Portugal. Commissioned by the Health Action International Europe. 2009.
Decree-Law No. 152/2012 of July 12, Diário da República, 1. the N-series. 134, July 12, 2012.
Decree-Law No. 176/2006, Diário da República n. 167/2006, Series I of August 30, in its current writing.
Directive 2001/83/EC of the European Parliament and the Council of 6 November 2001 establishing a community code on medicinal products for human use. Official Journal n o L 311 of 28/11/2001 p 0067 - 0128.
Regulation (EC) No 726/2004 of the European Parliament and the Council of 31 March 2004 establishing Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Relevant Text for EEA purposes). Jornal Oficial no L 136 of 30/04/2004 p 0001 - 0033.
INFARMED. I.P., Infomed - Database of medicines for human use. Accessed on: 8 Apr 2022. Available in: https://extranet. infarmed.pt/INFOMED-fo/.
INFARMED, I.P., Market Monitoring Report. Available in: https://www.infarmed.pt/web/infarmed/entidades/medicamentos-uso-humano/monitorizacao-mercado. Accessed on: 8 Apr 2022.
WORLD HEALTH ORGANIZATION (WHO). Seventy-second world health assembly Geneva, 20-28 May 2019 Resolutions and Decisions Annexes.
Ordinance No. 548/88, Diário da República n. the 187, Series I, August 13, 1988.
Ordinance No. 29/90, Diário da República n. the 11, Series I, January 13, 1990.
Directive 89/105/EEC of 21 December 1988, Official Journal of the European Communities, N. L 40/8-11, 11.2.89.
Decree-Law No 65/2007, Diário da República, 1a series, No 52, 14 March 2007.
Decree-Law No. 134/2005, Diário da República n. o 154, Series I-A, August 16.
Ordinance No. 827/2005, Diário da República n. the 177, Series I-B, September 14, 2005.
Vogler S, Zimmermann N, Haasis MA, et al. Pharmaceutical pricing and reimbursement policies in 47 PPRI network member countries Authors. 2019.
Ordinance No. 280/2021, Diário da República, 1a série, N. 234, Page 48-50 of 3 December 2021.
Decree-Law No. 81/90, Diário da República - I Série N. 59, March 12, 1990.
Ordinance No. 195-C/2015, of June 30, 2015, in the essay conferred on it by Ordinance No. 290-A/2016, of November 15, Diário da República n. 219/2016, 1supplement, Series I of November 15.
Martins J, Cardoso F, Guerra L. How are drug prices formed? 1a. Focus, editor. 2017.
ODS. Ensure access to quality health and promote well-being for all, at all ages. 2022 Available in: https://www.ods.pt/objectivos/3-vida-saudavel/?portfolioCats=24. Accessed on: 13 Apr 2022.
Decree-Law No. 97/2015 of June 1, 2015, in the wording conferred on it by Decree-Law no. o 115/2017, of September 7, Diário da República n. o 173/2017, Series I 2017-09-07, pages 5316 - 5332.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
